Asia-Pacific

InnoCare Pharma has received NMPA clearance to trial ICP-B161, a long-acting bispecific antibody targeting two key IBD pathways, in China.

BioNexus Gene Lab will build AI document-processing applications for Malaysia's public healthcare digitisation programme under a ten-year exclusive licence.

Rua Bioscience will distribute PharmAla's GMP-grade LaNeo MDMA to authorised New Zealand psychiatrists following Medsafe's September approval for PTSD treatment.

Editas has received ethics and regulatory approval in Australia to begin its Phase 1/2 Strive trial of in vivo gene editor EDIT-401 in

Nasdaq-listed Cuprina is buying East Coast Podiatry and Orchard Clinic to integrate clinical delivery with its wound-care and collagen technologies.

The PD-L1/4-1BB bispecific antibody has now secured orphan drug designation in Japan, the US, and Europe, as its China NDA enters technical

The deal gives Crystal Crop exclusive India rights to Cibus gene-editing technology targeting higher mustard yields across 8.5 million hectares.

China's CDE has granted Breakthrough Therapy Designation to NXP200, a brain-penetrant BRAF inhibitor, for recurrent BRAF V600-mutant high-grade glioma.

Adagene's double-masked T-cell engager ADG138 cleared China's NMPA for a Phase 1 solid tumour trial due to start in Q4 2026.

Opamtistomig's Phase IIb registrational results in advanced EP-NEC will headline ESMO 2026, alongside three Proffered Paper presentations from the Nanjing biotech.

CUE-221 met both primary and key secondary endpoints in a 145-patient Phase 2 study, with the 4 mg/kg dose outperforming omalizumab 12

Capricor Therapeutics will show HOPE-3 skeletal and cardiac outcomes data at the World Muscle Society Congress ahead of its November BLA action date.

ByteDance's AI drug discovery spin-off Anew Labs has closed a reported $290m first external round, led by HSG, IDG Capital and Hillhouse Investment.

Japan's MHLW has approved Elixir Medical's DynamX bioadaptor for coronary artery disease, creating a new device category in the country.

Phase II data for the PD-L1/4-1BB bispecific showed consistent responses regardless of PD-L1 expression, as an NDA advances under NMPA priority

MediLink's B7-H3 ADC beat topotecan on overall survival and response rate in 451-patient Chinese trial, with an NDA now accepted by China

China's NMPA has accepted the NCX 470 glaucoma NDA filed by Nicox's licensee Ocumension, with a regulatory decision expected within 12 to 18

Lakeland's Hong Kong subsidiary has secured a follow-on contract to supply flame-resistant foul weather suits to Hong Kong Government Flying Service pilots

The NASDAQ-listed operator said paid membership surged 40% to over 210,000 in under seven weeks, as it builds toward an AI-enabled care

The Chinese battery maker says Model 32140 shipments doubled year-on-year as it targets India's fast-growing light electric vehicle market.